Your browser doesn't support javascript.
loading
The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort.
Touroutoglou, Alexandra; Katsumi, Yuta; Brickhouse, Michael; Zaitsev, Alexander; Eckbo, Ryan; Aisen, Paul; Beckett, Laurel; Dage, Jeffrey L; Eloyan, Ani; Foroud, Tatiana; Ghetti, Bernardino; Griffin, Percy; Hammers, Dustin; Jack, Clifford R; Kramer, Joel H; Iaccarino, Leonardo; Joie, Renaud La; Mundada, Nidhi S; Koeppe, Robert; Kukull, Walter A; Murray, Melissa E; Nudelman, Kelly; Polsinelli, Angelina J; Rumbaugh, Malia; Soleimani-Meigooni, David N; Toga, Arthur; Vemuri, Prashanthi; Atri, Alireza; Day, Gregory S; Duara, Ranjan; Graff-Radford, Neill R; Honig, Lawrence S; Jones, David T; Masdeu, Joseph C; Mendez, Mario F; Musiek, Erik; Onyike, Chiadi U; Riddle, Meghan; Rogalski, Emily; Salloway, Stephen; Sha, Sharon; Turner, R Scott; Wingo, Thomas S; Wolk, David A; Womack, Kyle; Carrillo, Maria C; Rabinovici, Gil D; Apostolova, Liana G; Dickerson, Bradford C.
Afiliación
  • Touroutoglou A; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Katsumi Y; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Brickhouse M; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Zaitsev A; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Eckbo R; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Aisen P; Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Beckett L; Department of Public Health Sciences, University of California - Davis, Davis, California, USA.
  • Dage JL; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Eloyan A; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Foroud T; Department of Biostatistics, Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
  • Ghetti B; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Griffin P; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Hammers D; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Jack CR; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Kramer JH; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Iaccarino L; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Joie R; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Mundada NS; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Koeppe R; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Kukull WA; Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
  • Murray ME; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Nudelman K; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
  • Polsinelli AJ; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Rumbaugh M; Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Soleimani-Meigooni DN; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Toga A; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
  • Vemuri P; Laboratory of Neuro Imaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of USC, Los Angeles, California, USA.
  • Atri A; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Day GS; Banner Sun Health Research Institute, Sun City, Arizona, USA.
  • Duara R; Department of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
  • Graff-Radford NR; Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami, Florida, USA.
  • Honig LS; Department of Neurology, Mayo Clinic in Florida, Jacksonville, Florida, USA.
  • Jones DT; Taub Institute and Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA.
  • Masdeu JC; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
  • Mendez MF; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Musiek E; Nantz National Alzheimer Center, Houston Methodist and Weill Cornell Medicine, Houston, Texas, USA.
  • Onyike CU; Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Riddle M; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Rogalski E; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Salloway S; Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Sha S; Department of Psychiatry and Behavioral Sciences, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Turner RS; Department of Neurology, Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Wingo TS; Department of Neurology & Neurological Sciences, Stanford University, Palo Alto, California, USA.
  • Wolk DA; Department of Neurology, Georgetown University, Washington, D.C., USA.
  • Womack K; Department of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Carrillo MC; Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Rabinovici GD; Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
  • Apostolova LG; Medical & Scientific Relations Division, Alzheimer's Association, Chicago, Illinois, USA.
  • Dickerson BC; Department of Neurology, University of California - San Francisco, San Francisco, California, USA.
Alzheimers Dement ; 19 Suppl 9: S74-S88, 2023 11.
Article en En | MEDLINE | ID: mdl-37850549
ABSTRACT

INTRODUCTION:

Magnetic resonance imaging (MRI) research has advanced our understanding of neurodegeneration in sporadic early-onset Alzheimer's disease (EOAD) but studies include small samples, mostly amnestic EOAD, and have not focused on developing an MRI biomarker.

METHODS:

We analyzed MRI scans to define the sporadic EOAD-signature atrophy in a small sample (n = 25) of Massachusetts General Hospital (MGH) EOAD patients, investigated its reproducibility in the large longitudinal early-onset Alzheimer's disease study (LEADS) sample (n = 211), and investigated the relationship of the magnitude of atrophy with cognitive impairment.

RESULTS:

The EOAD-signature atrophy was replicated across the two cohorts, with prominent atrophy in the caudal lateral temporal cortex, inferior parietal lobule, and posterior cingulate and precuneus cortices, and with relative sparing of the medial temporal lobe. The magnitude of EOAD-signature atrophy was associated with the severity of cognitive impairment.

DISCUSSION:

The EOAD-signature atrophy is a reliable and clinically valid biomarker of AD-related neurodegeneration that could be used in clinical trials for EOAD. HIGHLIGHTS We developed an early-onset Alzheimer's disease (EOAD)-signature of atrophy based on magnetic resonance imaging (MRI) scans. EOAD signature was robustly reproducible across two independent patient cohorts. EOAD signature included prominent atrophy in parietal and posterior temporal cortex. The EOAD-signature atrophy was associated with the severity of cognitive impairment. EOAD signature is a reliable and clinically valid biomarker of neurodegeneration.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Humans Idioma: En Revista: Alzheimers Dement Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos